Resolving Cancer Heterogeneity:



Similar documents
International symposium on: The Impact of Genomic Deep Sequencing on

International Symposium on: Pain and Cough

Scientific Programme

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom

Promises and challenges of developing new drugs in oncology

Promises and challenges of developing new drugs in oncology

CONTRASTS IN PHARMACOLOGY 2.0

LIQUID BIOPSY: TRACKING CANCER

58th ANNUAL MEETING OF THE ITALIAN CANCER SOCIETY REVOLUTIONARY ROAD. VERONA SEPTEMBER Palazzo della GRAN GUARDIA. First Announcement

The Copernican Revolution in Ischemic Heart Diseases: the day after

A LIFE THAT IS BORN MAKES LIFE GROW. CORD BLOOD: CURRENT EXPERIENCES AND FUTURE PROGRAMMES

Scientific Programme

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities

on End Stage Focus on Idiopathic

2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

Nuevas tecnologías basadas en biomarcadores para oncología

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

Genomics in Hematology

Aging and Chronic Diseases

Targeted Therapy What the Surgeon Needs to Know

CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010

Colorectal cancer xenopatients: A preclinical platform for precision medicine

Stem Cells, Cancer, Immunology and Aging

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)

Breast Pathology Masterclass 2016

Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

IV Molecular Cytopathology Focus on Next Generation Sequencing in Cytopathology

INTERDISCIPLINARY CONFERENCE. Florence/Firenze, Italy Nov 27-29, 2012 Centro Congressi al Duomo, Firenze BREAST SEMINAR SERIES

International Colloquium on Cardio-Oncology

FAMILIAL CANCER ESO, CNIO AND NRCO CONFERENCE ON May 2016 Madrid, Spain. Chairs: R. Eeles, UK W.D. Foulkes, CA M. Robledo, ES H.

Stem Cells, Cancer, Immunology and Aging

Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy

INTERNATIONAL RETREAT OF PhD STUDENTS IN IMMUNOLOGY June 2015

Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, Malmö, Sweden. Primary Objective:

ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN

Future Directions in Cancer Research What does is mean for medical physicists and AAPM?

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

FOCUS ON BIOLOGICAL THERAPIES IN HEMATOLOGIC MALIGNANCIES

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

FIRST ITALIAN CHAPTER MEETING

Advances in Biology and Treatment of Malignant Brain Gliomas

The following information is only meant for people who have been diagnosed with advanced non-small cell

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN

Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents

Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children

PERSONALIZED CANCER TREATMENT A multidisciplinary event

How To Learn More About Melanoma

A leader in the development and application of information technology to prevent and treat disease.

Future Oncology: Technology, Products, Market and Service Opportunities

Per maggiori informazioni

Regional Young Investigator SIC meeting. 5-6 March 2015

Cancer Survivorship Care

CRS workshop 21 st -23 rd November 2013

Nephrolithiasis: a systemic disorder

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

Curriculum Vitae - Sara Gandini

SPEAKERS AND CHAIRMEN

EACR AACR SIC. from Cancer Biology to the Clinic. Advance Programme & Call for Abstracts ITALY JUNE. Anticancer Drug Action and Drug Resistance:

ON CLINICAL PHARMACOLOGY OF ANTIRETROVIRALS 10 RESIDENTIAL COURSE January Starhotels Majestic. corso Vittorio Emanuele II 54 - TURIN

How can we generate economic value from personalized medicine and big data analysis?

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Houston Cancer Institute

THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS

eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl

UICC World Cancer Congress. Cancer Staging and Quality of Care

Advances in Lung Cancer: A Multidisciplinary Approach

BREAST CANCER IN YOUNG WOMEN. OCTOBER 9 th 2015 Aula Magna UNIVERSITÀ DELLA SVIZZERA ITALIANA Lugano

Oncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis

Haploidentical Stem Cell Transplantation

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Magnetic Resonance Techniques in Neurodegenerative Diseases First Course Alzheimer s disease and frontotemporal lobar degeneration spectrum

HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE.

2016 PANCREATIC CANCER ACTION NETWORK PRECISION PROMISE CLINICAL TRIAL CONSORTIUM SITES. Guidelines and Application Instructions

THE PRESENT AND THE FUTURE OF FERTILITY PRESERVATION

targeted therapy a guide for the patient

CARDIOVASCULAR DISEASE AND COPD

Mediterranean School of Oncology

Transcription:

INTERNATIONAL SYMPOSIUM ON: Resolving Cancer Heterogeneity: The way to personalised medicine Palazzo della Gran Guardia Verona (Italy), June 30 th July 2 nd, 2016 PROGRAM Organized by: ARC-Net Centre for Applied Research on Cancer University of Verona (Italy) Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston (Texas, USA)

Co-Presidents of the Symposium - Aldo Scarpa - Department of Pathology and Diagnostics ARC-Net Centre for Applied Research on Cancer University of Verona (Italy) - Ignacio I. Wistuba - Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston (Texas, USA) Promoted by Fondazione Internazionale Menarini Centro Direzionale Milanofiori Edificio L - Strada 6 20089 Rozzano (Milan, Italy) Phone: +39 02 55308110 - Fax: +39 02 55305739 milan@fondazione-menarini.it - www.fondazione-menarini.it Organizing Secretariat DueCi Promotion srl Via C. Farini, 28-40124 Bologna (Italy) Phone: +39 051 4841310 - Fax: +39 051 247165 ggrillenzoni@duecipromotion.com - www.duecipromotion.com

- Program - Thursday, June 30 th, 2016 - Afternoon - Opening ceremony 06:00 p.m. 06:15 p.m. 07:00 p.m. Welcome Addresses Aldo Scarpa (Verona, I) and Ignacio I. Wistuba (Houston, USA) Co-Presidents Anirban Maitra (Houston, USA) Emerging targets from the pancreatic cancer genome Welcome cocktail Friday, July 1 st, 2016 - Morning - Treatment decision-making in solid tumors: the unaddressed needs Session I Chairperson: Filippo de Braud (Milan, I) 08:30 a.m. 09:00 a.m. 09:30 a.m. 10:00 a.m. 10:30 a.m. 11:00 a.m. 11:30 a.m. 12:00 p.m. 12:30 p.m. 01:00 p.m. Dario Marchetti (Houston, USA) Dissecting mechanisms of breast cancer dormancy: the isolation and interrogation of patient-derived CTC subsets Daniela Cesselli (Udine, I) Identification of circulating tumor cells in epithelial-to-mesenchymal transition in metastatic breast cancer patients Anna Sapino (Torino, I) Assessing tumor heterogeneity in breast cancer Pierfranco Conte Change of molecular characteristic and breast cancer progression Coffee break Nikolas Stoecklein (Dusseldorf, D) Genomic profiling of HNSCC on the single cell level indicates metastasis-relevant genes Giorgio Stanta (Trieste, I) Functional and not clonal heterogeneity: practical approaches Klaus Pantel (Hamburg, D) Liquid biopsy: implications for cancer therapy Lunch

Friday, July 1 st, 2016 - Afternoon - Intra and inter-tumor heterogeneity: current issues and treatment efficacy Session II Chairperson: Aldo Scarpa (Verona, I) 02:00 p.m. 02:30 p.m. 03:00 p.m. 03:30 p.m. 04:00 p.m. 04:30 p.m. 05:00 p.m. 05:30 p.m. 06:00 p.m. Paola Gazzaniga (Rome, I) Molecular features of circulating tumor cells in lung cancer patients treated with checkpoint inhibitors: avoiding predation Justo P. Castaño Fuentes (Còrdoba, E) Splicing defects as a novel factor contributing to tumor development and heterogeneity Peter Metrakos (Montreal, CDN) Heterogeneity in colorectal cancer metastasis and response to therapy Coffee break Tatsuhiro Shibata (Tokio, J) Liver cancer heterogeneity Samra Turajlic (London, UK) Mapping renal cancer evolution through space and time Pamela Pinzani (Florence, I) Mutational analysis of single circulating tumor cells Saturday, July 2 nd, 2016 - Morning - Limitations of tumor biopsy & technology solutions Session III Chairperson: 08.30 a.m. 09.00 a.m. 09.30 a.m. 10.00 a.m. 10.30 a.m. 11.00 a.m. 11.30 a.m. 12.00 p.m. 12.30 p.m. 01.00 p.m. 01.30 p.m. Ignacio I. Wistuba (Houston, USA) Catherine Alix-Panabieres (Montpelliér, F) Detection, characterization and ex vivo expansion of viable circulating tumor cells Rafael Rosell (Barcellona, E) Future perspectives for treatment strategies in EGFR mutant NSCLC Giampaolo Tortora (Verona, I) Clinical translation of biomolecular studies in pancreas cancer patients Zofia Piotrowska (Boston, USA) Heterogeneity of resistance mechanisms in EGFR-mutant NSCLC Coffee break Jianjun Zhang (Houston, USA) The potential impact of intra-tumor heterogeneity on biopsy and molecular profiling in lung cancer Johann de Bono (London, UK) Molecular predictive biomarkers for target agents in prostate cancer Aldo Scarpa (Verona, I) Identification of potentially druggable pathways in solid cancers by molecular profiling via next generation sequencing Lunch

- General Information - Meeting venue The venue for the symposium is Palazzo della Gran Guardia Piazza Bra, 1 - Verona Official language The official language of the meeting will be English. Simultaneous translation will not be provided. Attendees registration The symposium is free to attend, but on line registration is required. Please link to the organizing secretariat website: www.duecipromotion.com/ Congressi Medici / Calendario Congressi / Registrazione on line On line registrations will be accepted on a first-come, first-served basis and may be closed in advance whenever the maximum number of participants allowed in the venue will be reached. Registration includes: Access to scientific sessions, welcome cocktail, coffee breaks, lunch, program book, certificate of attendance.

Fondazione Internazionale Menarini Symposia n: 290 agfmilano.com